The development of molecular agents targeting the EGFR pathway offers attractive avenues for anti-tumor effects, and the presently available EGFR tyrosine kinase inhibitors in widespread clinical use are gefitinib and erlotinib (Ayati et al., 2021). This evidence concerns the gene EGFR and neoplasm.